Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases: A Prospective, Open-Label, Randomised, Controlled Trial

Liver Metastases ◽

Controlled Trial ◽

Open Label ◽

Colorectal Cancer Liver Metastases ◽

Synchronous Colorectal Cancer ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(18)30269-3 ◽

2018 ◽

Vol 3 (12) ◽

pp. 845-855 ◽

Cited By ~ 5

Author(s):

Alvaro Romera ◽

Sergiy Peredpaya ◽

Yaroslav Shparyk ◽

Igor Bondarenko ◽

Giovanni Mendonça Bariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomised Controlled ◽

First Line Treatment

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(08)60455-9 ◽

2008 ◽

Vol 371 (9617) ◽

pp. 1007-1016 ◽

Cited By ~ 1258

Author(s):

Bernard Nordlinger ◽

Halfdan Sorbye ◽

Bengt Glimelius ◽

Graeme J Poston ◽

Peter M Schlag ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Controlled Trial ◽

Perioperative Chemotherapy ◽

Intergroup Trial ◽

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30862-9 ◽

2020 ◽

Vol 21 (4) ◽

pp. 497-507 ◽

Cited By ~ 28

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30027-0 ◽

2019 ◽

Vol 20 (6) ◽

pp. 849-861 ◽

Cited By ~ 74

Author(s):

Cathy Eng ◽

Tae Won Kim ◽

Johanna Bendell ◽

Guillem Argilés ◽

Niall C Tebbutt ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated ◽

PWE-290 An open-label, randomised controlled trial comparing the efficacy of intravenous and oral iron in the preoperative management of colorectal cancer anaemia: ivica trial

Gut ◽

10.1136/gutjnl-2015-309861.736 ◽

2015 ◽

Vol 64 (Suppl 1) ◽

pp. A339.1-A339 ◽

Cited By ~ 2

Author(s):

BD Keeler ◽

JA Simpson ◽

O Ng ◽

H Padmanabhan ◽

MJ Brookes ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Oral Iron ◽

Preoperative Management ◽

Open Label ◽

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Faculty Opinions recommendation of Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12032956.13172054 ◽

2011 ◽

Author(s):

Carlos Seas ◽

Jorge Alave

Keyword(s):

Enteric Fever ◽

Controlled Trial ◽

Open Label ◽

Faculty Opinions recommendation of Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13368964.14739064 ◽

2011 ◽

Author(s):

Vineet Bhandari

Keyword(s):

Mechanical Ventilation ◽

Preterm Infants ◽

Controlled Trial ◽

Open Label ◽

Surfactant Treatment ◽

Randomised Controlled ◽

Spontaneously Breathing

Faculty Opinions recommendation of Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13827960.15267062 ◽

2012 ◽

Author(s):

Weijing Sun ◽

Davendra Sohal

Keyword(s):

Gastric Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

D2 Gastrectomy ◽